Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
SERA 
Sera Prognostics Inc (SERA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: SERA (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $2.75
1 Year Target Price $2.75
| 2 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 35.36% | Avg. Invested days 24 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 127.13M USD | Price to earnings Ratio - | 1Y Target Price 2.75 |
Price to earnings Ratio - | 1Y Target Price 2.75 | ||
Volume (30-day avg) 2 | Beta 0.97 | 52 Weeks Range 1.37 - 9.13 | Updated Date 10/17/2025 |
52 Weeks Range 1.37 - 9.13 | Updated Date 10/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.85 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -54823.53% |
Management Effectiveness
Return on Assets (TTM) -23.42% | Return on Equity (TTM) -44.24% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 79324646 | Price to Sales(TTM) 1177.1 |
Enterprise Value 79324646 | Price to Sales(TTM) 1177.1 | ||
Enterprise Value to Revenue 734.49 | Enterprise Value to EBITDA -0.61 | Shares Outstanding 37094109 | Shares Floating 24428107 |
Shares Outstanding 37094109 | Shares Floating 24428107 | ||
Percent Insiders 10.78 | Percent Institutions 61.47 |
Upturn AI SWOT
Sera Prognostics Inc
Company Overview
History and Background
Sera Prognostics Inc. is a womenu2019s health diagnostics company focused on improving outcomes through early prediction of preterm birth risk. Founded in 2010, the company has developed and commercialized PreTRM, a blood test designed to predict the risk of spontaneous preterm birth in pregnant women.
Core Business Areas
- Preterm Birth Prediction: The company's primary business revolves around the development and commercialization of diagnostic tests for predicting preterm birth risk.
- Women's Health Diagnostics: Sera Prognostics is focused on expanding its product offerings in womenu2019s health beyond preterm birth prediction.
Leadership and Structure
Sera Prognostics is led by a management team with experience in diagnostics, women's health, and commercialization. The company has a board of directors with expertise in the healthcare industry.
Top Products and Market Share
Key Offerings
- PreTRM Test: PreTRM is a blood test designed to predict the risk of spontaneous preterm birth in singleton pregnancies. Market share is still developing. Competitors include companies developing alternative preterm birth prediction methods, such as biochemical markers and ultrasound technologies.
Market Dynamics
Industry Overview
The diagnostics industry is focused on developing tools for early disease detection and risk prediction. The preterm birth prediction market is driven by the need to improve maternal and infant health outcomes.
Positioning
Sera Prognostics aims to be a leader in preterm birth prediction and women's health diagnostics. Their competitive advantage lies in the clinical validation and proprietary technology behind the PreTRM test.
Total Addressable Market (TAM)
The estimated TAM is several billion USD, considering the prevalence of preterm birth globally. Sera is positioned to capture a significant share through wider adoption and reimbursement for PreTRM.
Upturn SWOT Analysis
Strengths
- Clinically validated PreTRM test
- Proprietary proteomic technology
- Focus on a significant unmet medical need
Weaknesses
- Limited commercial traction
- Dependence on single product (PreTRM)
- Requires significant resources for market adoption
Opportunities
- Expansion into new geographic markets
- Development of new diagnostic tests for women's health
- Partnerships with healthcare providers and payers
Threats
- Competition from alternative preterm birth prediction methods
- Regulatory hurdles for new diagnostic tests
- Reimbursement challenges
Competitors and Market Share
Key Competitors
- SQNM
- ILMN
- ROCHE.SW
Competitive Landscape
Sera Prognostics is a small player compared to larger diagnostic companies. Sera's advantage lies in its focus on preterm birth prediction and proprietary technology.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited due to the recent commercialization of PreTRM.
Future Projections: Future growth is dependent on increasing market adoption and reimbursement coverage for PreTRM.
Recent Initiatives: Recent initiatives include expanding the sales force, securing reimbursement contracts, and developing new clinical studies.
Summary
Sera Prognostics is a company focused on improving womenu2019s health through diagnostic testing. The company has a promising technology, but faces significant challenges in commercialization and reimbursement. The company must achieve sustainable growth to provide shareholder returns. The market is competitive and the road ahead is uncertain.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Market Research Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market data is dynamic and can change rapidly.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Sera Prognostics Inc
Exchange NASDAQ | Headquaters Salt Lake City, UT, United States | ||
IPO Launch date 2021-07-15 | President, CEO & Director Ms. Evguenia Lindgardt M.B.A. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 63 | Website https://www.sera.com |
Full time employees 63 | Website https://www.sera.com | ||
Sera Prognostics, Inc., a women's health company, discovers, develops, and commercializes blood-based biomarker tests and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman for the prediction of the expectant mother's risk of delivering spontaneously. It is also developing a pipeline of novel blood-based biomarker tests for major pregnancy-related conditions, including time-to-birth, predictive analytics product, pregnancy risk prediction panel, preeclampsia, and fetal growth restriction. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.